Deceased kidney transplantation with thymoglobulin versus anti-IL2R monoclonal antibody induction - A paired kidney analysis

Bibliographic Details
Main Author: Oliveira, Cláudia Maria Costa de
Publication Date: 2011
Other Authors: Gomes, Diego Morais, Reuber, Camilo, Santos, Daniela Costa de Oliveira, Oliveira, Maria Luisa Mattos Brito, Fernandes, Paula Castelo Branco, Evangelista Júnior, João, Esmeraldo, Ronaldo Matos
Format: Article
Language: por
Source: Brazilian Journal of Transplantation
Download full: https://bjt.emnuvens.com.br/revista/article/view/200
Summary: Purpose: Thymoglobulin is an important polyclonal antibody used in kidney transplantation as an induction therapy, and it has been asso- ciated to a decrease in delayed graft function and acute rejection rates. The authors used a paired kidney analysis to compare thymoglobulin with other induction therapies, in order to minimize the donor variabilility and bias. Methods: All paired kidneys from deceased donors during the period 2006-2008, where one kidney was allocated to a patient receiving thymoglobulin (group1) and its mate allocated to a pa- tient receiving anti IL-2R monoclonal antibodies (group 2) were assessed in this retrospective study. To investigate the impact of induction therapy, we investigated the delayed graft function rates (DGF), acute rejection (AR) and renal function in the first year after the transplant (Tx) in the paired kidney subjects. Results: A total of 94 Txs were investigated: mean age: 38.4 years, being 60.6 % male and with average dialysis time of 4.11 yrs. No statistically significant difference was found between both groups in relation to the recipient age, gender, HLA mismatches, PRA, cold ischemia time (CIT). Immunosuppressive protocol consisted to mofetil mycophenolate plus calcineurin inhibitors (tacrolimus in 88.3% of patients) in both groups, and steroids in 62% of patients. Deceased donor characteristics were: 63.8% male, mean age 30.9 ys, serum creatinine 1.17 mg/dl. The most important causes of death were trauma in 48.9% and cerebrovascular accident in 19.1% donors. The magnitude of renal function at 3, 6 and 12 post-Tx months and the DGF rate (56.6% vs 63.0%) were not statistically different between both groups. The rate of any AR report within 1 post-Tx year was significantly lower in the Thymo group (19.6 vs 45.7%; p = 0.008), and the incidence of CMV disease was similar in both groups (10.9 vs 15.2%; p = 0.535). Conclusion: Thymoglobulin was associated to a significant reduction in 1 yr-acute rejection rate in this cohort of paired kidneys, but without presenting a decreased DGF rate. There was no impact on renal function/CMV disease in the 1st post-Tx year.
id ABTO_94f2f0a3ae9a1418f5ff05e39c499893
oai_identifier_str oai:ojs3.emnuvens.com.br:article/200
network_acronym_str ABTO
network_name_str Brazilian Journal of Transplantation
repository_id_str
spelling Deceased kidney transplantation with thymoglobulin versus anti-IL2R monoclonal antibody induction - A paired kidney analysisTERAPIA DE INDUÇÃO COM TIMOGLOBULINA VERSUS ANTICORPO MONOCLONAL ANTI - IL2R - UMA ANÁLISE PAREADA EM TRANSPLANTE RENAL COM DOADOR FALECIDOTransplante RenalImunosupressãoDoador FalecidoGlobulina AntilinfocitáriaAnticorpos MonoclonaisKidney TransplantationImmunosuppressionDeceased DonorAntilymphocyte globulinAntibodies, MonoclonalPurpose: Thymoglobulin is an important polyclonal antibody used in kidney transplantation as an induction therapy, and it has been asso- ciated to a decrease in delayed graft function and acute rejection rates. The authors used a paired kidney analysis to compare thymoglobulin with other induction therapies, in order to minimize the donor variabilility and bias. Methods: All paired kidneys from deceased donors during the period 2006-2008, where one kidney was allocated to a patient receiving thymoglobulin (group1) and its mate allocated to a pa- tient receiving anti IL-2R monoclonal antibodies (group 2) were assessed in this retrospective study. To investigate the impact of induction therapy, we investigated the delayed graft function rates (DGF), acute rejection (AR) and renal function in the first year after the transplant (Tx) in the paired kidney subjects. Results: A total of 94 Txs were investigated: mean age: 38.4 years, being 60.6 % male and with average dialysis time of 4.11 yrs. No statistically significant difference was found between both groups in relation to the recipient age, gender, HLA mismatches, PRA, cold ischemia time (CIT). Immunosuppressive protocol consisted to mofetil mycophenolate plus calcineurin inhibitors (tacrolimus in 88.3% of patients) in both groups, and steroids in 62% of patients. Deceased donor characteristics were: 63.8% male, mean age 30.9 ys, serum creatinine 1.17 mg/dl. The most important causes of death were trauma in 48.9% and cerebrovascular accident in 19.1% donors. The magnitude of renal function at 3, 6 and 12 post-Tx months and the DGF rate (56.6% vs 63.0%) were not statistically different between both groups. The rate of any AR report within 1 post-Tx year was significantly lower in the Thymo group (19.6 vs 45.7%; p = 0.008), and the incidence of CMV disease was similar in both groups (10.9 vs 15.2%; p = 0.535). Conclusion: Thymoglobulin was associated to a significant reduction in 1 yr-acute rejection rate in this cohort of paired kidneys, but without presenting a decreased DGF rate. There was no impact on renal function/CMV disease in the 1st post-Tx year.Introdução: A timoglobulina é um anticorpo policlonal utilizado na terapia de indução em transplante (Tx) renal e que tem sido associado à redução na incidência de função retardada do enxerto (DGF) e rejeição aguda. Objetivo: Comparar terapia de indução com timoglobulina versus anticorpos monoclonais anti-IL2R em uma análise pareada de transplantes renais com doador falecido. Métodos:Todos os rins pareados de doador falecido no período de 2006-2008, onde um dos rins foi alocado para um paciente recebendo timoglobulina (grupo 1) e o seu par foi alocado para um paciente recebendo anticorpo monoclonal anti-IL2R (grupo 2) foram incluídos neste estudo retrospectivo. As taxas de DGF e rejeição aguda, a função renal e a incidência de doença por citomegalovírus (CMV), no primeiro ano de transplante, foram avaliadas. Resultados: Foram incluídos 94 receptores, idade média 38,4 anos, 60,6 % do sexo masculino e tempo médio em diálise 4,11 anos. Não houve diferença estatística entre os dois grupos em relação à idade e sexo do receptor, número de mismatches HLA, anticorpos reativos contra painel (PRA) e tempo de isquemia fria (TIF). O protocolo imunossupressor inicial consistiu de micofenolato mofetil e inibidor de calcineurina (tacrolimus: 88,3%) e prednisona em 62% dos pacientes. Em relação aos doadores, 63,8% eram do sexo masculino, idade média 30,9 anos, creatinina sérica 1,17 mg/dl, causas da morte encefálica: traumatismo crânio-encefálico em 48,9% e acidente vascular cerebral em 19,1%. A função renal avaliada pela creatinina aos três, seis e doze meses pós-Tx, a incidência de DGF (56,6 vs 63,0%) e de CMV doença (10,9 vs 15,2%) não foi estatisticamente diferente entre os grupos. A taxa de rejeição aguda foi significativamente menor no grupo da timoglobulina (19,6 vs 45,7%; p = 0,008). Conclusão: A terapia de indução com timoglobulina associou-se com uma redução significativa na incidência de rejeição aguda no primeiro ano de transplante nessa coorte de receptores de rins pareados de doador falecido. Não foi detectada redução na taxa de DGF e não houve impacto na função renal/ incidência de CMV doença com o uso da timoglobulina.Associação Brasileira de Transplante de Órgãos (ABTO)2011-03-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://bjt.emnuvens.com.br/revista/article/view/20010.53855/bjt.v14i2.200Brazilian Journal of Transplantation; Vol. 14 No. 2 (2011); 1518-1522Brazilian Journal of Transplantation; v. 14 n. 2 (2011); 1518-15222764-1589reponame:Brazilian Journal of Transplantationinstname:Associação Brasileira de Transplante de Órgãos (ABTO)instacron:ABTOporhttps://bjt.emnuvens.com.br/revista/article/view/200/187Copyright (c) 2021 Brazilian Journal of Transplantationinfo:eu-repo/semantics/openAccessOliveira, Cláudia Maria Costa deGomes, Diego MoraisReuber, CamiloSantos, Daniela Costa de OliveiraOliveira, Maria Luisa Mattos Brito Fernandes, Paula Castelo BrancoEvangelista Júnior, JoãoEsmeraldo, Ronaldo Matos2021-09-28T14:28:53Zoai:ojs3.emnuvens.com.br:article/200Revistahttps://bjt.emnuvens.com.br/revistaONGhttps://bjt.emnuvens.com.br/revista/oaibjt@abto.org.brhttps://doi.org/10.53855/2764-15892764-1589opendoar:2021-09-28T14:28:53Brazilian Journal of Transplantation - Associação Brasileira de Transplante de Órgãos (ABTO)false
dc.title.none.fl_str_mv Deceased kidney transplantation with thymoglobulin versus anti-IL2R monoclonal antibody induction - A paired kidney analysis
TERAPIA DE INDUÇÃO COM TIMOGLOBULINA VERSUS ANTICORPO MONOCLONAL ANTI - IL2R - UMA ANÁLISE PAREADA EM TRANSPLANTE RENAL COM DOADOR FALECIDO
title Deceased kidney transplantation with thymoglobulin versus anti-IL2R monoclonal antibody induction - A paired kidney analysis
spellingShingle Deceased kidney transplantation with thymoglobulin versus anti-IL2R monoclonal antibody induction - A paired kidney analysis
Oliveira, Cláudia Maria Costa de
Transplante Renal
Imunosupressão
Doador Falecido
Globulina Antilinfocitária
Anticorpos Monoclonais
Kidney Transplantation
Immunosuppression
Deceased Donor
Antilymphocyte globulin
Antibodies, Monoclonal
title_short Deceased kidney transplantation with thymoglobulin versus anti-IL2R monoclonal antibody induction - A paired kidney analysis
title_full Deceased kidney transplantation with thymoglobulin versus anti-IL2R monoclonal antibody induction - A paired kidney analysis
title_fullStr Deceased kidney transplantation with thymoglobulin versus anti-IL2R monoclonal antibody induction - A paired kidney analysis
title_full_unstemmed Deceased kidney transplantation with thymoglobulin versus anti-IL2R monoclonal antibody induction - A paired kidney analysis
title_sort Deceased kidney transplantation with thymoglobulin versus anti-IL2R monoclonal antibody induction - A paired kidney analysis
author Oliveira, Cláudia Maria Costa de
author_facet Oliveira, Cláudia Maria Costa de
Gomes, Diego Morais
Reuber, Camilo
Santos, Daniela Costa de Oliveira
Oliveira, Maria Luisa Mattos Brito
Fernandes, Paula Castelo Branco
Evangelista Júnior, João
Esmeraldo, Ronaldo Matos
author_role author
author2 Gomes, Diego Morais
Reuber, Camilo
Santos, Daniela Costa de Oliveira
Oliveira, Maria Luisa Mattos Brito
Fernandes, Paula Castelo Branco
Evangelista Júnior, João
Esmeraldo, Ronaldo Matos
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Oliveira, Cláudia Maria Costa de
Gomes, Diego Morais
Reuber, Camilo
Santos, Daniela Costa de Oliveira
Oliveira, Maria Luisa Mattos Brito
Fernandes, Paula Castelo Branco
Evangelista Júnior, João
Esmeraldo, Ronaldo Matos
dc.subject.por.fl_str_mv Transplante Renal
Imunosupressão
Doador Falecido
Globulina Antilinfocitária
Anticorpos Monoclonais
Kidney Transplantation
Immunosuppression
Deceased Donor
Antilymphocyte globulin
Antibodies, Monoclonal
topic Transplante Renal
Imunosupressão
Doador Falecido
Globulina Antilinfocitária
Anticorpos Monoclonais
Kidney Transplantation
Immunosuppression
Deceased Donor
Antilymphocyte globulin
Antibodies, Monoclonal
description Purpose: Thymoglobulin is an important polyclonal antibody used in kidney transplantation as an induction therapy, and it has been asso- ciated to a decrease in delayed graft function and acute rejection rates. The authors used a paired kidney analysis to compare thymoglobulin with other induction therapies, in order to minimize the donor variabilility and bias. Methods: All paired kidneys from deceased donors during the period 2006-2008, where one kidney was allocated to a patient receiving thymoglobulin (group1) and its mate allocated to a pa- tient receiving anti IL-2R monoclonal antibodies (group 2) were assessed in this retrospective study. To investigate the impact of induction therapy, we investigated the delayed graft function rates (DGF), acute rejection (AR) and renal function in the first year after the transplant (Tx) in the paired kidney subjects. Results: A total of 94 Txs were investigated: mean age: 38.4 years, being 60.6 % male and with average dialysis time of 4.11 yrs. No statistically significant difference was found between both groups in relation to the recipient age, gender, HLA mismatches, PRA, cold ischemia time (CIT). Immunosuppressive protocol consisted to mofetil mycophenolate plus calcineurin inhibitors (tacrolimus in 88.3% of patients) in both groups, and steroids in 62% of patients. Deceased donor characteristics were: 63.8% male, mean age 30.9 ys, serum creatinine 1.17 mg/dl. The most important causes of death were trauma in 48.9% and cerebrovascular accident in 19.1% donors. The magnitude of renal function at 3, 6 and 12 post-Tx months and the DGF rate (56.6% vs 63.0%) were not statistically different between both groups. The rate of any AR report within 1 post-Tx year was significantly lower in the Thymo group (19.6 vs 45.7%; p = 0.008), and the incidence of CMV disease was similar in both groups (10.9 vs 15.2%; p = 0.535). Conclusion: Thymoglobulin was associated to a significant reduction in 1 yr-acute rejection rate in this cohort of paired kidneys, but without presenting a decreased DGF rate. There was no impact on renal function/CMV disease in the 1st post-Tx year.
publishDate 2011
dc.date.none.fl_str_mv 2011-03-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://bjt.emnuvens.com.br/revista/article/view/200
10.53855/bjt.v14i2.200
url https://bjt.emnuvens.com.br/revista/article/view/200
identifier_str_mv 10.53855/bjt.v14i2.200
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://bjt.emnuvens.com.br/revista/article/view/200/187
dc.rights.driver.fl_str_mv Copyright (c) 2021 Brazilian Journal of Transplantation
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2021 Brazilian Journal of Transplantation
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Associação Brasileira de Transplante de Órgãos (ABTO)
publisher.none.fl_str_mv Associação Brasileira de Transplante de Órgãos (ABTO)
dc.source.none.fl_str_mv Brazilian Journal of Transplantation; Vol. 14 No. 2 (2011); 1518-1522
Brazilian Journal of Transplantation; v. 14 n. 2 (2011); 1518-1522
2764-1589
reponame:Brazilian Journal of Transplantation
instname:Associação Brasileira de Transplante de Órgãos (ABTO)
instacron:ABTO
instname_str Associação Brasileira de Transplante de Órgãos (ABTO)
instacron_str ABTO
institution ABTO
reponame_str Brazilian Journal of Transplantation
collection Brazilian Journal of Transplantation
repository.name.fl_str_mv Brazilian Journal of Transplantation - Associação Brasileira de Transplante de Órgãos (ABTO)
repository.mail.fl_str_mv bjt@abto.org.br
_version_ 1836111233464401920